As of 2024-12-15, the EV/EBITDA ratio of Spero Therapeutics Inc (SPRO) is 16.31. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SPRO's latest enterprise value is -17.95 mil USD. SPRO's TTM EBITDA according to its financial statements is -1.10 mil USD. Dividing these 2 quantities gives us the above SPRO EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 15.1x | 13.8x |
| Forward P/E multiples | 13.4x - 15.3x | 15.0x |
| Fair Price | 1.17 - 7.92 | 4.46 |
| Upside | 9.3% - 640.5% | 316.6% |
| Date | EV/EBITDA |
| 2024-12-13 | 16.31 |
| 2024-12-12 | 14.82 |
| 2024-12-11 | 12.35 |
| 2024-12-10 | 12.10 |
| 2024-12-09 | 12.84 |
| 2024-12-06 | 11.35 |
| 2024-12-05 | 11.85 |
| 2024-12-04 | 10.86 |
| 2024-12-03 | 11.85 |
| 2024-12-02 | 13.34 |
| 2024-11-29 | 12.84 |
| 2024-11-27 | 13.34 |
| 2024-11-26 | 13.34 |
| 2024-11-25 | 12.35 |
| 2024-11-22 | 11.85 |
| 2024-11-21 | 10.36 |
| 2024-11-20 | 9.87 |
| 2024-11-19 | 11.85 |
| 2024-11-18 | 12.84 |
| 2024-11-15 | 10.86 |
| 2024-11-14 | 7.39 |
| 2024-11-13 | 4.42 |
| 2024-11-12 | 3.93 |
| 2024-11-11 | 3.43 |
| 2024-11-08 | 3.93 |
| 2024-11-07 | 4.42 |
| 2024-11-06 | 4.42 |
| 2024-11-05 | 4.42 |
| 2024-11-04 | 5.41 |
| 2024-11-01 | 10.86 |
| 2024-10-31 | 8.38 |
| 2024-10-30 | 5.41 |
| 2024-10-29 | 4.42 |
| 2024-10-28 | 5.41 |
| 2024-10-25 | 3.43 |
| 2024-10-24 | 6.90 |
| 2024-10-23 | 6.90 |
| 2024-10-22 | 6.40 |
| 2024-10-21 | 5.91 |
| 2024-10-18 | 5.91 |
| 2024-10-17 | 5.66 |
| 2024-10-16 | 7.89 |
| 2024-10-15 | 9.87 |
| 2024-10-14 | 8.38 |
| 2024-10-11 | 7.39 |
| 2024-10-10 | 7.89 |
| 2024-10-09 | 7.89 |
| 2024-10-08 | 7.89 |
| 2024-10-07 | 4.92 |
| 2024-10-04 | 4.92 |